Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4UQ2B
|
|||
| Drug Name |
KITE-222
|
|||
| Drug Type |
CAR-T cell therapy
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Company |
Gilead
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid inhibitory C-type lectin-like receptor (CD371) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04789408) A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Gilead | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.